China India cooperation! Highlights of international fan'er Forum

The 10th China (Taizhou) International Pharmaceutical Expo, hosted by the people's Government of Jiangsu Province, opened in the exhibition center of China Pharmaceutical City, Taizhou, Jiangsu Province on September 18, 2019 The pharmaceutical Expo lasted for 3 days, among which, the 10th China (Taizhou) International Pharmaceutical Expo, chemical drug R & D and international development forum, sponsored by China Pharmaceutical City, hosted by pharmaceutical intelligence network and co organized by high level talents Association of Taizhou pharmaceutical high tech Zone, was successfully held in the afternoon of that day Taizhou medical Expo helped domestic pharmaceutical enterprises to go out of the country and understand the frontier international policies Government leaders, senior experts in the industry, and senior executives of well-known enterprises gathered together to conduct in-depth analysis and Discussion on the theme of "focusing on industrial hot spots and stepping into the international journey", to talk about new trends, seize opportunities and meet challenges Dr Li Jinbing, member of the Party Working Committee and deputy director of the Management Committee of Taizhou pharmaceutical high tech Zone, made an overall report on the construction and development of China Pharmaceutical city in the past 12 years First, the level of industrial agglomeration has been continuously improved At present, more than 1000 foreign pharmaceutical enterprises have gathered, including 12 well-known global multinational enterprises such as Nestle, AstraZeneca and bringer Ingelheim; second, the pace of industrialization has been accelerated, 35 pharmaceutical manufacturers have obtained production licenses, and 50 production lines of 20 enterprises have been put into production through GMP certification; third, the recruitment of high-end talents has achieved fruitful results More than 3200 high-level biomedical talents at home and abroad have been introduced in total, ranking among the best in the similar parks in the country Fourthly, the construction of innovation system has been solidly promoted, and has been approved as a national innovative industrial cluster pilot China Pharmaceutical city has become the largest biomedical industry base with the most complete industrial chain in China Taizhou, with a long history and a famous cultural city, has a history of more than 2100 years It has been the political, economic, cultural and transportation center of Central Jiangsu since ancient times It is known as the "Valley County of Han and Tang Dynasties and the famous Huaihai district" Taizhou is now a developing new industrial city Chen Yuyu, director of Investment Promotion Bureau of Taizhou pharmaceutical high tech Industrial Park Management Committee, made a detailed introduction to Taizhou and the only national high tech Zone in China, Taizhou pharmaceutical high tech Industrial Development Zone Dr Li Jinbing, member of the Party Working Committee and deputy director of the Management Committee of Taizhou pharmaceutical high tech Industrial Park, Chen Yuyu, director of the Investment Promotion Bureau of the Management Committee of Taizhou pharmaceutical high tech Industrial Park, released the list of comprehensive strength of chemical drugs of Chinese listed pharmaceutical enterprises in 2019 at the highlight of the conference! Among them, Jiangsu Hengrui Pharmaceutical Co., Ltd., dongyangguang Pharmaceutical Co., Ltd., Sichuan Kelun Pharmaceutical Co., Ltd., Shiyao Holding Group Co., Ltd., Tianshili Pharmaceutical Group Co., Ltd., Zhejiang XinHeCheng Co., Ltd., Zhengda Tianqing Pharmaceutical Group Co., Ltd., Shandong Lukang Pharmaceutical Co., Ltd., humanwell Pharmaceutical Group Co., Ltd and other innovative companies Pharmaceutical enterprises with new strength have been successfully shortlisted Chen Yuyu, director of Investment Promotion Bureau of Taizhou pharmaceutical high tech Industrial Park Management Committee, Fu Xueqi, chairman of Shenzhen Tianyi Technology Development Co., Ltd and Jiangsu Tianyi Pharmaceutical Co., Ltd., and Li Tianquan, co-founder of pharmaceutical intelligence network, came on stage to award medals to the winning enterprises In order to affirm and encourage these excellent enterprises, the organizing committee has made full use of industry data, established scientific data model, and ensured the scientificity and fairness of this list based on the rules of open review, which has raised the attention of all sectors of the society to the development of medicine How to make a breakthrough in the research and development of generic drugs at the awarding ceremony of "ranking list of comprehensive strength of chemical drugs of Chinese listed pharmaceutical enterprises in 2019"? Is it feasible to integrate internationalization step by step? "In the post-4 + 7 era, there are four countermeasures They are integration of raw materials and preparations, improved new drugs, and consistency evaluation of innovative drugs and generic drugs " Dr Zhang naturan, specially invited vice president of China Chemical Pharmaceutical Industry Association, mentioned that raw material preparation is a strong field in China, and the total number of application for improved new drugs is increasing year by year, accounting for 74% of the total generic name Innovative drugs are the development trend in the process of internationalization, and the consistency evaluation of generic drugs is fierce The production of generic drugs before considered profit, and now considered survival At the round table forum, Zhang Tianyi, general manager of Fangda Pharmaceutical (China), said that "there are two kinds of internationalization, one is the internationalization of generic drugs, the other is the internationalization of new drugs." With the interests of generic drugs being constantly compressed, should Chinese enterprises follow the general trend and develop innovative drugs? "Enterprises should first put themselves in an international position, and look at high standards, all powerful enterprises should follow the path of internationalization." Sun Liying, founder of Santai Technology Co., Ltd and Beijing Santai cloud Technology Co., Ltd., said Mr Wang xiangxu, chairman of Shanghai Huyuan Pharmaceutical Co., Ltd., holds a different point of view "For enterprises with weak domestic market, they should first develop themselves and then enter the international market." Zhang Tianyi, general manager of Fangda Pharmaceutical (China), said: "we should position ourselves according to the actual situation of the enterprise, such as whether you have a R & D team and sales conditions overseas We do not recommend advocating internationalization all the time If the top 50 enterprises of generic drugs in China naturally rush to the international market, but the innovative drugs are not the same, no matter how strong the enterprises are, as long as there are innovative technologies, they may be able to make a big impact on the international market " How to establish R & D projects in the post-4 + 7 era after the frequent highlights of the round table forum and how to expand the scope of Dr Zhang natural, specially invited vice president of China Chemical Pharmaceutical Industry Association, and how to conduct R & D projects in the face of new drug procurement platform? Dr Zhang naturan, vice president of China Chemical Pharmaceutical Industry Association, pointed out the bright road for the guests on site Among them, the development of innovative drugs and international integration is the trend, but there is still a huge market space for generic drugs Medical insurance is a large-scale poverty alleviation project With the gradual implementation of the 4 + 7 policy, the space for drug prices has been compressed It is also a suitable development route to accelerate the development of generic drugs and improve the replacement rate of original research Murali variyath, senior general manager of heterolabs Limited of China and India's product development scenario India & China, this year, the State Drug Administration and the central drug standard control bureau of India held a "China India drug regulatory exchange meeting", and India's entry into China has become the focus of the industry Mr murali variyath, senior general manager of heterolabs limited, shared many opportunities for cooperation between China and India in the conference hall, and believed that there are many similarities between the development of China and India's pharmaceutical industry As a big exporter of APIs, how China can successfully transform in the process of globalization and how to cooperate with multinational enterprises is a smooth way Similarities, differences and development trends of new drug approval between China and the United States "Differences in concepts, systems, systems, requirements, and outcomes lead to differences in approval between China and the United States" Sun Liying, chief medical officer and strategy officer of hermetic pharmaceutical, founder of Santai and Beijing Santai cloud Technology Co., Ltd., once worked for the U.S FDA, has great experience in drug registration and approval in the United States By analyzing and comparing the policy similarities and differences between China and the United States, we can learn from the successful experience of the United States Innovative drug research and development is the driving force for the development of national pharmaceutical industry As the strongest country in the world, the United States is closely related to the technical support and policy encouragement given by the food and Drug Administration in the process of new drug approval In addition, Mr Li Tianquan, co-founder and vice president of yaozhi.com, made an in-depth analysis on the progress and trend of the internationalization of China's chemical industry The pharmaceutical and chemical industry is an important field related to the national economy and people's livelihood, and an important guarantee for promoting the construction of a healthy China Mr Zhang Tianyi, general manager of Fangda Pharmaceutical (China), made an open discussion on the clinical development strategy of the China us new drug dual newspaper, Focusing on new drug creation and experimental research; Mr Wang xiangxu, chairman of Shanghai Huyuan Pharmaceutical Co., Ltd., gave a vivid speech on the development of Indian drugs India has considerable cooperation potential and overseas research and development potential in research and development, chemical pharmacy, etc in the past 30 years, India's market share of generic drugs has remained at a high level It is the mission and vision of pharmaceutical intelligence network to build a professional forum of pharmaceutical industry to promote the development of China's pharmaceutical health industry The forum was successfully held with rich contents The industry members gathered together and offered suggestions, which played a positive role in promoting the development of the pharmaceutical industry in the future Taizhou medical Expo exhibition area has a wonderful glimpse of the cooperation of China Medical City: Project attraction and financial support of China Medical City Please contact the head of China Merchants Bureau: Chen Yuyu 13775668699, scan code and wechat